Jacob, Yael http://orcid.org/0000-0003-3278-9264
Morris, Laurel S. http://orcid.org/0000-0002-5862-6650
Verma, Gaurav
Rutter, Sarah B.
Balchandani, Priti
Murrough, James W. http://orcid.org/0000-0001-6286-1242
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01 MH109544, R01MH109544)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 24 January 2022
Revised: 4 May 2022
Accepted: 10 May 2022
First Online: 19 May 2022
Competing interests
: Dr. Priti Balchandani is a named inventor on patents relating to magnetic resonance imaging (MRI) and RF pulse design. The patents have been licensed to GE Healthcare, Siemens AG, and Philips international. Dr. Balchandani receives royalty payments relating to these patents. In the past 5 years, Dr. Murrough has provided consultation services and/or served on advisory boards for Boehringer Ingelheim, Clexio Biosciences, Engrail Therapeutics, FSV7, Global Medical Education (GME), Otsuka, and Sage Therapeutics. Dr. Murrough is named on a patent-pending for neuropeptide Y as a treatment for mood and anxiety disorders and on a patent pending for the use of KCNQ channel openers to treat depression and related conditions. The Icahn School of Medicine (employer of Dr. Murrough) is named on a patent and has entered into a licensing agreement and will receive payments related to the use of ketamine or esketamine for the treatment of depression. The Icahn School of Medicine is also named on a patent related to the use of ketamine for the treatment of PTSD. Dr. Murrough is not named on these patents and will not receive any payments. No other authors reported biomedical financial interests or potential conflicts of interest.